For the second study in the Kinect series, we were again charged with recruiting patients who suffer from tardive dyskinesia (TD), a condition characterized by involuntary facial and body movements in people who have schizophrenia or schizoaffective disorder. Like the first Kinect Study, the Kinect 2 Study was testing a treatment option to help reduce the severity of TD symptoms. Maintaining our core message, we targeted patients and caregivers in a respectful way to encourage participation in the study.
Our online advertising campaign generated more than 12 million impressions to our target audience and provided nearly 44,000 visitors to the study website. We were also able to work with 20 different organizations to facilitate sponsorships that helped spread the word about the condition and the study across many communities.
At a Glance